Focus on Alternative and Complementary Therapies
www.pharmpress.com/fact
Focus Alternat Complement Ther©2005 Pharmaceutical Press
Focus Altern Complement Ther 2003; 8: 505
To examine the effectiveness of Phellinus baumii.
The subjects consisted of three postoperative cancer patients that took 0.5–1.5 g/day of P. baumii.
Case 1: A 44-year-old woman was diagnosed with sigmoid colon cancer and metastases in liver, lung and rectum were observed. After an operation for sigmoid colon cancer, fluorouracil and levofolinatecalcium were administered but she had severe side-effects. Then she started taking 1.0 g/day of P. baumii and the side-effects disappeared 10 days later and reduced size of the meta-static cancers was observed.
Case 2: A 62-year-old man underwent removal of his left kidney because renal cell carcinoma was diagnosed. Three months after the operation, a slight increase in immunosuppressive acidic protein (IAP) was observed and interferon-alpha administration was started. But the interferon administration was replaced by a prescription of 0.5–1.5 g/day of P. baumii. Ten months after the start of this prescription, the IAP level began to decrease and the patient did not develop side-effects.
Case 3: A 42-year-old woman was diagnosed with rectal cancer and the primary cancer was removed. Fluorouracil, levofolinatecalcium and P. baumii were administered. The patients did not develop side-effects and the carcinoembryonic antigen level decreased and natural killer-cell activity increased.
Phellinus baumii is considered to be effective in reducing various severe side-effects of antitumour drugs. Both antitumour effect and an apparent decrease of side-effects can be expected when using P. baumii for postoperative cancer patients.
